Resistant hypertension (RH)—blood pressure that remains above goal despite the concurrent use of three different classes of antihypertensive drugs at optimal doses, including a diuretic—is a common and dangerous clinical challenge. Patients with RH face significantly higher risks of stroke, heart attack, and kidney failure.
For years, RH was viewed as a problem of simple non-adherence or lifestyle factors. However, a wealth of peer-reviewed evidence has identified a powerful, often-missed culprit: Primary Aldosteronism (PA). Screening for PA in these patients is not just a clinical guideline; it is an urgent necessity for providing targeted, curative, or highly effective treatment.
The Epidemic of a Missed Diagnosis
Primary Aldosteronism is a condition where the adrenal glands produce too much of the hormone aldosterone, independent of the body’s normal regulatory systems (the renin-angiotensin system). This aldosterone excess causes the kidneys to retain salt and water, suppressing plasma renin activity and driving up blood pressure.
While once considered a rare cause of hypertension, studies have demonstrated its surprisingly high prevalence, particularly in the most severe cases:
- High Prevalence: PA is estimated to be present in 5% to 10% of all hypertensive individuals, but this figure skyrockets to 15% to 30% in patients with resistant hypertension. This makes it the most common curable cause of secondary hypertension.
- The Screening Gap: Despite clinical guidelines recommending screening for PA in all RH patients, real-world data reveals a massive discrepancy. Studies show that screening rates for PA among eligible patients with resistant hypertension are distressingly low, often falling below 5% in general practice settings. This means that a large majority of patients with a potentially curable or highly treatable disease are being missed.
Beyond Blood Pressure: The Risk of Aldosterone Toxicity
The danger of PA extends far beyond simply elevating blood pressure. Excess aldosterone has direct cytotoxic and pro-fibrotic effects on organs, independent of its effect on blood pressure.
Compared to patients with essential hypertension at the same BP level, those with untreated PA face:
- Increased Cardiovascular Risk: Studies have consistently shown PA patients have a 4- to 12-fold higher rate of non-fatal myocardial infarction, stroke, atrial fibrillation, and left ventricular hypertrophy.
- Renal Damage: The chronic stress from aldosterone excess accelerates the progression of chronic kidney disease.
- Hypokalemia is a Poor Indicator: The classic presentation of PA often included low potassium levels (hypokalemia). However, modern research shows that the most common presentation is actually normokalemic PA (normal potassium levels). Relying on hypokalemia as the trigger for screening is a major reason so many cases are missed.
The evidence is clear: identifying PA offers a profound opportunity to not only control blood pressure but also to significantly reduce cardiovascular and renal morbidity.
The Screening Protocol: Simple Test, Complex Impact
Screening for Primary Aldosteronism is a straightforward process involving a simple blood test: the Aldosterone-Renin Ratio (ARR).
- The Test: The ARR measures the Plasma Aldosterone Concentration (PAC) and the Plasma Renin Activity (PRA). A high PAC combined with suppressed PRA yields a high ARR, which is the hallmark of PA.
- Medication Challenges: To obtain the most accurate results, certain medications (particularly mineralocorticoid receptor antagonists and some diuretics) should ideally be withdrawn for several weeks, if clinically feasible. However, with the rising awareness of the screening gap, newer guidelines increasingly support performing the screening test while the patient is on most existing antihypertensive medications. If the result is clearly positive, it confirms the diagnosis; if it’s borderline, medications can be adjusted for re-testing.
- Confirmatory Steps and Subtyping: A positive ARR screening requires follow-up, typically with a confirmatory test (like a salt-loading or fludrocortisone suppression test) and imaging. The final critical step is adrenal venous sampling (AVS), which determines if the excess aldosterone is coming from one side (unilateral, potentially curable with surgery) or both sides (bilateral, requiring medical management).
Targeted Therapy: A Path to Cure and Control
A confirmed diagnosis of PA shifts management from a trial-and-error approach to a highly targeted treatment plan:
- Surgical Cure (Unilateral PA): If AVS confirms that one adrenal gland is responsible (often due to an aldosterone-producing adenoma), a laparoscopic adrenalectomy can be performed. This can cure the hypertension in a significant proportion of patients and completely resolve the aldosterone excess, offering a genuine long-term solution.
- Medical Management (Bilateral PA): For patients with bilateral disease, the gold-standard treatment is the use of Mineralocorticoid Receptor Antagonists (MRAs), such as spironolactone or eplerenone. These drugs directly block the harmful effects of aldosterone. Even in cases of resistant hypertension without PA, MRAs are often effective as a fourth-line agent, a response likely due to an unrecognized degree of functional aldosterone excess.
The dramatic response to MRAs in RH patients—often showing a significant drop in blood pressure—underscores the pivotal role of aldosterone in treatment resistance. By integrating aggressive PA screening into the management of resistant hypertension, clinicians can move beyond simple symptom management to address the fundamental, and often curable, hormonal drivers of the disease, dramatically improving patient longevity and quality of life.
